Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTP-011
- Development stage
- Preclinical
- Lead developer
- GT Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GTP-011 is a repurposed drug candidate developed for the treatment of **motion sickness**. It is described as a reformulation or repurposed version of an **existing drug**, specifically designed to treat symptoms associated with motion sickness. Publicly available information does not disclose the original drug's identity, the precise molecular target, or its detailed mechanism of action. GTP-011 has not been identified in clinical trial registries, nor is there published data about its development status beyond its use as a motion sickness treatment. It was developed within the Oxis International/GT Biopharma portfolio[1][3][5].
Beyond the preview
Go deeper on GTP-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTP-011.